Migraine new drug El Jian oral small molecule Ubrelvy approved today

Migraines are a very common chronic diseaseAccording to the World Health Organization (WHO), one in ten people in the world suffers from migraines, three times as many as menPatients often develop seizures of the disease, which include headaches, fear of light, fear of sound, hallucinations, and nauseaCurrently, the common drug for acute migraines is the queratinHowever, such drugs have side effects that cause blood vessel contraction, so patients at risk of cardiovascular disease cannot use themCGRP has gone through a long scientific research and drug development process from its initial discovery to being a hot target for migraine treatmentIn the 1990s, Professor Peter Goadsby of the University of California, San Francisco (UCSF), first discovered that the level of CGRP in the blood of patients increased during migraine attacks, and found that CGRP released by the trigeminal nervous system was the "switch" that triggered migraine attacksThe findings identified the nerve source of migraines and made the CGRP signaling pathway a popular target for the treatment of migrainescgRP causes migraines (Photo: Molecular Medicine)However, the development of drugs for CGRP receptor inhibitors has not been easy, and the initial development of small molecules OF CGRP receptor antagonists has had an effect in relieving headaches, but the liver toxicity of long-term use of them has halted the development processOn the other hand, the development of antibody-based therapies targeting CGRP receptors or CGRP itself has been successfulThese antibodies, due to their long half-life, can effectively reduce the number of migraine episodes in patients by being injected monthly or even once every three monthsThree antibody drugs have been approved by the FDAThese include Aimovig and Amgen, a joint development of Aimovig and Amgen, Ajovy (fremanezumab-vfrm) in Teva, and Eli Lilly The Ubrelvy, developed by Galcanezumab-gnlmEljian, is a new generation of small molecule CGRP receptor antagonists, with a different structure than the previous generation of small molecule antagonists, effectively solving the problem of liver toxicityIts efficacy has been demonstrated in two randomized double-blind trials involving 1,439 migraine patients, including placebo-controlledIn both trials, patients treated with Ubrelvy had significantly better rates of painlessness and the disappearance of other major migraine symptoms within two hours of treatment than in the placebo group "Migraines are often a degenerative disease," said Dr Billy Dunn, acting director of the Office of Neuroscience at the FDA's Center for Drug Evaluation and Research In addition to Aer Ken's Ubrelvy, Biohaven Pharmaceuticals' oral CGRP receptor inhibitor, Rimegepant, is currently under FDA review and is expected to be approved early next year It has also just received a clinical license in China, where it is expected to conduct clinical trials to treat migraine patients There are other CGRP receptor inhibitors in the research pipeline of Eljian and Biohaven that are developing small molecules Recently, Biohaven developed the first nasal dose of the CGRP receptor antagonist vazegepant in phase 2/3 of the key clinical trials also reached the main endpoint related reading: Oral migraine new drug is coming! CGRP receptor inhibitor rimegepant in China approved clinical we look forward to the day as more innovative drugs emerge, the day of human getting rid of migraines will come soon References: Hoyd December 23, 2019, from https:// CGRP as the target of the new migraine therapies - CGRP as the target of the new migraine sipries - translation from the bench to clinic Nature Reviews Neurology https://doi.org/10.1038/s41582-018-0003-1 Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for The Acute Treatment of Migraine Retrieved October 13, 2019, from https:// Here's the story of its discovery-and-its.com Retrieved October 13, 2019, from https:// Expert Opinion on The Al Drugs, DOI: 10.1080/13543784.2019.1618830 original title: Milestones! First oral small molecule CGRP receptor inhibitor approved today to treat migraines